Sandra E Juul1, Phuong T Vu2,3, Bryan A Comstock2, Rajan Wadhawan4, Dennis E Mayock1, Sherry E Courtney5, Tonya Robinson6, Kaashif A Ahmad7, Ellen Bendel-Stenzel8, Mariana Baserga9, Edmund F LaGamma10, L Corbin Downey11, Michael O'Shea12, Raghavendra Rao12, Nancy Fahim12, Andrea Lampland13, Ivan D Frantz14, Janine Khan15, Michael Weiss16, Maureen M Gilmore17, Robin Ohls18, Nishant Srinivasan19, Jorge E Perez20, Victor McKay21, Patrick J Heagerty2. 1. Division of Neonatology, Department of Pediatrics, University of Washington, Seattle. 2. Department of Biostatistics, University of Washington, Seattle. 3. now with Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington. 4. Department of Neonatal-Perinatal Medicine, AdventHealth, Orlando, Florida. 5. Division of Neonatology, Department of Pediatrics, University of Arkansas, Little Rock. 6. Division of Neonatology, Department of Pediatrics, University of Louisville, Louisville, Kentucky. 7. Department of Neonatal Medicine, Methodist Children's Hospital, San Antonio, Texas. 8. Department of Neonatology, Children's Minnesota, Minneapolis. 9. Division of Neonatology, Department of Pediatrics, University of Utah, Salt Lake City. 10. Department of Neonatal Medicine, Maria Fareri Children's Hospital at Westchester, Valhalla, New York. 11. Division of Neonatology, Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina. 12. Division of Neonatology, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis. 13. Department of Neonatology, Children's Minnesota, St Paul. 14. Division of Neonatology, Department of Pediatrics, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 15. Division of Neonatology, Department of Pediatrics, Prentice Women's Hospital, Chicago, Illinois. 16. Division of Neonatology, Department of Pediatrics, University of Florida, Gainesville. 17. Division of Neonatology, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland. 18. Division of Neonatology, Department of Pediatrics, University of New Mexico, Albuquerque. 19. Department of Pediatrics, Children's Hospital of the University of Illinois, Chicago. 20. Department of Neonatology, South Miami Hospital, South Miami, Florida. 21. Department of Neonatology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
Abstract
Importance: Extremely preterm infants are among the populations receiving the highest levels of transfusions. Erythropoietin has not been recommended for premature infants because most studies have not demonstrated a decrease in donor exposure. Objectives: To determine whether high-dose erythropoietin given within 24 hours of birth through postmenstrual age of 32 completed weeks will decrease the need for blood transfusions. Design, Setting, and Participants: The Preterm Erythropoietin Neuroprotection Trial (PENUT) is a randomized, double-masked clinical trial with participants enrolled at 19 sites consisting of 30 neonatal intensive care units across the United States. Participants were born at a gestational age of 24 weeks (0-6 days) to 27 weeks (6-7 days). Exclusion criteria included conditions known to affect neurodevelopmental outcomes. Of 3266 patients screened, 2325 were excluded, and 941 were enrolled and randomized toerythropoietin (n = 477) or placebo (n = 464). Data were collected from December 12, 2013, to February 25, 2019, and analyzed from March 1 to June 15, 2019. Interventions: In this post hoc analysis, erythropoietin, 1000 U/kg, or placebo was given every 48 hours for 6 doses, followed by 400 U/kg or sham injections 3 times a week through postmenstrual age of 32 weeks. Main Outcomes and Measures: Need for transfusion, transfusion numbers and volume, number of donor exposures, and lowest daily hematocrit level are presented herein. Results:A total of 936 patients (488 male [52.1%]) were included in the analysis, with a mean (SD) gestational age of 25.6 (1.2) weeks and mean (SD) birth weight of 799 (189) g. Erythropoietin treatment (vs placebo) decreased the number of transfusions (unadjusted mean [SD], 3.5 [4.0] vs 5.2 [4.4]), with a relative rate (RR) of 0.66 (95% CI, 0.59-0.75); the cumulative transfused volume (mean [SD], 47.6 [60.4] vs 76.3 [68.2] mL), with a mean difference of -25.7 (95% CI, 18.1-33.3) mL; and donor exposure (mean [SD], 1.6 [1.7] vs 2.4 [2.0]), with an RR of 0.67 (95% CI, 0.58-0.77). Despite fewer transfusions, erythropoietin-treated infants tended to have higher hematocrit levels than placebo-treated infants, most noticeable at gestational week 33 in infants with a gestational age of 27 weeks (mean [SD] hematocrit level in erythropoietin-treated vs placebo-treated cohorts, 36.9% [5.5%] vs 30.4% [4.6%] (P < .001). Of 936 infants, 160 (17.1%) remained transfusion free at the end of 12 postnatal weeks, including 43 in the placebogroup and 117 in the erythropoietin group (P < .001). Conclusions and Relevance: These findings suggest that high-dose erythropoietin as used in the PENUT protocol was effective in reducing transfusion needs in this population of extremely preterm infants. Trial Registration: ClinicalTrials.gov Identifier: NCT01378273.
RCT Entities:
Importance: Extremely preterm infants are among the populations receiving the highest levels of transfusions. Erythropoietin has not been recommended for premature infants because most studies have not demonstrated a decrease in donor exposure. Objectives: To determine whether high-dose erythropoietin given within 24 hours of birth through postmenstrual age of 32 completed weeks will decrease the need for blood transfusions. Design, Setting, and Participants: The Preterm Erythropoietin Neuroprotection Trial (PENUT) is a randomized, double-masked clinical trial with participants enrolled at 19 sites consisting of 30 neonatal intensive care units across the United States. Participants were born at a gestational age of 24 weeks (0-6 days) to 27 weeks (6-7 days). Exclusion criteria included conditions known to affect neurodevelopmental outcomes. Of 3266 patients screened, 2325 were excluded, and 941 were enrolled and randomized to erythropoietin (n = 477) or placebo (n = 464). Data were collected from December 12, 2013, to February 25, 2019, and analyzed from March 1 to June 15, 2019. Interventions: In this post hoc analysis, erythropoietin, 1000 U/kg, or placebo was given every 48 hours for 6 doses, followed by 400 U/kg or sham injections 3 times a week through postmenstrual age of 32 weeks. Main Outcomes and Measures: Need for transfusion, transfusion numbers and volume, number of donor exposures, and lowest daily hematocrit level are presented herein. Results: A total of 936 patients (488 male [52.1%]) were included in the analysis, with a mean (SD) gestational age of 25.6 (1.2) weeks and mean (SD) birth weight of 799 (189) g. Erythropoietin treatment (vs placebo) decreased the number of transfusions (unadjusted mean [SD], 3.5 [4.0] vs 5.2 [4.4]), with a relative rate (RR) of 0.66 (95% CI, 0.59-0.75); the cumulative transfused volume (mean [SD], 47.6 [60.4] vs 76.3 [68.2] mL), with a mean difference of -25.7 (95% CI, 18.1-33.3) mL; and donor exposure (mean [SD], 1.6 [1.7] vs 2.4 [2.0]), with an RR of 0.67 (95% CI, 0.58-0.77). Despite fewer transfusions, erythropoietin-treated infants tended to have higher hematocrit levels than placebo-treated infants, most noticeable at gestational week 33 in infants with a gestational age of 27 weeks (mean [SD] hematocrit level in erythropoietin-treated vs placebo-treated cohorts, 36.9% [5.5%] vs 30.4% [4.6%] (P < .001). Of 936 infants, 160 (17.1%) remained transfusion free at the end of 12 postnatal weeks, including 43 in the placebo group and 117 in the erythropoietin group (P < .001). Conclusions and Relevance: These findings suggest that high-dose erythropoietin as used in the PENUT protocol was effective in reducing transfusion needs in this population of extremely preterm infants. Trial Registration: ClinicalTrials.gov Identifier: NCT01378273.
Authors: Raghavendra Rao; Kathleen Ennis; Gabriele R Lubach; Eric F Lock; Michael K Georgieff; Christopher L Coe Journal: Nutr Neurosci Date: 2016-08-06 Impact factor: 4.994
Authors: Tal Shafir; Rosa Angulo-Barroso; Yuezhou Jing; Mary Lu Angelilli; Sandra W Jacobson; Betsy Lozoff Journal: Early Hum Dev Date: 2008-02-12 Impact factor: 2.079
Authors: David C Kasper; John A Widness; Nadja Haiden; Angelika Berger; Michael Hayde; Arnold Pollak; Kurt R Herkner Journal: Neonatology Date: 2008-09-06 Impact factor: 4.035
Authors: Sangeeta Hingorani; Robert Schmicker; Kaashif A Ahmad; Ivan D Frantz; Dennis E Mayock; Edmund F La Gamma; Mariana Baserga; Janine Y Khan; Maureen M Gilmore; Tonya Robinson; Patrick Brophy; Patrick J Heagerty; Sandra E Juul; Stuart Goldstein; David Askenazi Journal: Clin J Am Soc Nephrol Date: 2022-07-19 Impact factor: 10.614
Authors: Minesh Khashu; Christof Dame; Pascal M Lavoie; Isabelle G De Plaen; Parvesh M Garg; Venkatesh Sampath; Atul Malhotra; Michael D Caplan; Praveen Kumar; Pankaj B Agrawal; Giuseppe Buonocore; Robert D Christensen; Akhil Maheshwari Journal: Newborn (Clarksville) Date: 2022-03-31
Authors: Timothy M Bahr; Diane M Ward; Xuan Jia; Robin K Ohls; Kendell R German; Robert D Christensen Journal: Blood Cells Mol Dis Date: 2021-01-06 Impact factor: 2.372
Authors: Willemien S Kalteren; Elise A Verhagen; Jonathan P Mintzer; Arend F Bos; Elisabeth M W Kooi Journal: Front Pediatr Date: 2021-02-26 Impact factor: 3.418